{"id":511603,"date":"2021-07-12T07:03:26","date_gmt":"2021-07-12T11:03:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\/"},"modified":"2021-07-12T07:03:26","modified_gmt":"2021-07-12T11:03:26","slug":"enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\/","title":{"rendered":"Enochian BioSciences Announces FDA Acceptance of Pre-IND Request  For Potential Cure for Hepatitis B Virus Infection"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">LOS ANGELES, July  12, 2021  (GLOBE NEWSWIRE) &#8212; (NASDAQ: ENOB) \u2013 Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that the FDA has accepted a Pre-IND (Investigational New Drug) request for a potential cure of hepatitis B virus (HBV) infection. Written comments are expected this Fall.<\/p>\n<p>The Pre-IND request was made based on promising data from a proof-of-concept study conducted in chimeric mice, considered by some scientific experts to be the \u2018gold standard\u2019 animal model to evaluate HBV cure.<\/p>\n<p>Dr. Mark Dybul, a prominent expert in viruses and Executive Vice Chairperson of the Board of Enochian BioSciences, said, \u201cAs a long-time researcher, clinician, and leader of large global disease programs, I am very pleased that the FDA accepted our request to provide feedback to our Hepatitis B development program, and welcome the agency\u2019s input. We are encouraged by the novel mechanism of action, called Hijack RNA that shows promise as a potential platform technology for coronaviruses (including the cause of COVID-19), influenza and HBV, and are exploring its use against HIV.\u201d<\/p>\n<p>Dr. Carol Brosgart, Clinical Professor of Medicine, Epidemiology and Biostatistics, UCSF and former Senior Advisor for Science and Policy to the Division of Viral Hepatitis at the Centers for Disease Control and Prevention, said, \u201cThe impressive results in the premier animal model gives me great hope that we are on track to develop a commercial product that could potentially cure HBV infection, a disease that causes chronic liver damage in ~350 million people globally and kills nearly 1 million people each year.\u201d Dr. Brosgart also served as former Vice President of Clinical Research at Gilead Sciences, responsible for HIV and HBV Drug Development, and is a Board Director of Enochian BioSciences.<\/p>\n<p>\n        <strong>About Enochian BioSciences, Inc.<\/strong><br \/>\n        <br \/>Enochian BioSciences, Inc. is a biopharmaceutical company focused on developing innovative platforms for gene-modified cellular and immune therapies to potentially cure and treat deadly diseases. The company\u2019s gene-modified cell and immune therapy platforms can potentially be applied to multiple indications, including HIV\/AIDS, Hepatitis B, all Corona and Influenza viruses, and Oncology. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5mISw5t2RSUtcxwt8d-7J3vQQyqqKj2NPkv_g2BvKqZot_RAWMj7GzyhQolJJR9mueDPXg6TGPE_qfJszV059r3LVJ_u-pioI5jIGRdWbbU=\" rel=\"nofollow noopener\" target=\"_blank\">Enochianbio.com<\/a><\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as \u201cbelieves,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201caims,\u201d \u201cintends,\u201d \u201cpotential,\u201d or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian BioSciences\u2019 most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian BioSciences undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQzMyM0MjkxNjU1IzIxMjA2Nzk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/21461e92-0ca8-48b6-8896-ea1ea163bb39\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Contact: ir@enochianbio.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LOS ANGELES, July 12, 2021 (GLOBE NEWSWIRE) &#8212; (NASDAQ: ENOB) \u2013 Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that the FDA has accepted a Pre-IND (Investigational New Drug) request for a potential cure of hepatitis B virus (HBV) infection. Written comments are expected this Fall. The Pre-IND request was made based on promising data from a proof-of-concept study conducted in chimeric mice, considered by some scientific experts to be the \u2018gold standard\u2019 animal model to evaluate HBV cure. Dr. Mark Dybul, a prominent expert in viruses and Executive Vice Chairperson of the Board of Enochian BioSciences, said, \u201cAs a long-time researcher, clinician, and leader of large global disease &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Enochian BioSciences Announces FDA Acceptance of Pre-IND Request  For Potential Cure for Hepatitis B Virus Infection&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-511603","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LOS ANGELES, July 12, 2021 (GLOBE NEWSWIRE) &#8212; (NASDAQ: ENOB) \u2013 Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that the FDA has accepted a Pre-IND (Investigational New Drug) request for a potential cure of hepatitis B virus (HBV) infection. Written comments are expected this Fall. The Pre-IND request was made based on promising data from a proof-of-concept study conducted in chimeric mice, considered by some scientific experts to be the \u2018gold standard\u2019 animal model to evaluate HBV cure. Dr. Mark Dybul, a prominent expert in viruses and Executive Vice Chairperson of the Board of Enochian BioSciences, said, \u201cAs a long-time researcher, clinician, and leader of large global disease &hellip; Continue reading &quot;Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-12T11:03:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQzMyM0MjkxNjU1IzIxMjA2Nzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection\",\"datePublished\":\"2021-07-12T11:03:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\\\/\"},\"wordCount\":538,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3ODQzMyM0MjkxNjU1IzIxMjA2Nzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\\\/\",\"name\":\"Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3ODQzMyM0MjkxNjU1IzIxMjA2Nzk=\",\"datePublished\":\"2021-07-12T11:03:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3ODQzMyM0MjkxNjU1IzIxMjA2Nzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3ODQzMyM0MjkxNjU1IzIxMjA2Nzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\/","og_locale":"en_US","og_type":"article","og_title":"Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection - Market Newsdesk","og_description":"LOS ANGELES, July 12, 2021 (GLOBE NEWSWIRE) &#8212; (NASDAQ: ENOB) \u2013 Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that the FDA has accepted a Pre-IND (Investigational New Drug) request for a potential cure of hepatitis B virus (HBV) infection. Written comments are expected this Fall. The Pre-IND request was made based on promising data from a proof-of-concept study conducted in chimeric mice, considered by some scientific experts to be the \u2018gold standard\u2019 animal model to evaluate HBV cure. Dr. Mark Dybul, a prominent expert in viruses and Executive Vice Chairperson of the Board of Enochian BioSciences, said, \u201cAs a long-time researcher, clinician, and leader of large global disease &hellip; Continue reading \"Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-12T11:03:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQzMyM0MjkxNjU1IzIxMjA2Nzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection","datePublished":"2021-07-12T11:03:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\/"},"wordCount":538,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQzMyM0MjkxNjU1IzIxMjA2Nzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\/","name":"Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQzMyM0MjkxNjU1IzIxMjA2Nzk=","datePublished":"2021-07-12T11:03:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQzMyM0MjkxNjU1IzIxMjA2Nzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3ODQzMyM0MjkxNjU1IzIxMjA2Nzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enochian-biosciences-announces-fda-acceptance-of-pre-ind-request-for-potential-cure-for-hepatitis-b-virus-infection\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/511603","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=511603"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/511603\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=511603"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=511603"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=511603"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}